Behind the Science

Is TB a thing of the past?

Experts Simon Tiberi and Kwame Shanaube discuss the biggest infectious disease killer in the world today – tuberculosis. Developed and funded by GSK. Show note: In this episode of Behind the Science , Dr. Kat Arney speaks with Dr Kwame Shanaube, Executive Director of Research at Zambart, and Professor Simon Tiberi, Senior Clinical Development Director at GSK, to unpack the challenges posed by TB – and what's being done to tackle them. If you want to hear more episodes, make sure to subscribe to the podcast. For more on how today’s discoveries are shaping tomorrow’s health, you can visit Behind the Science at GSK.com

• Transcript
• Chapters

Can science change the future of hepatitis B?

Experts Joyeta Das & Jessica Hicks discuss a disease that is so quiet and unassuming, it's often called 'the silent disease’ – Hepatitis B. Developed and funded by GSK. Show note: In the third Behind the Science episode, Dr. Kat Arney speaks with Jessica Hicks, Senior Director of the World Hepatitis Alliance, and Joyeta Das, Senior Global Medical Director for hepatitis B at GSK, to take a closer look at a disease that affects hundreds of millions of people worldwide. Around 87 million people in China and an estimated 1.7 million people in the United States are living with chronic hepatitis B, yet awareness and understanding of the disease remain low. Here we explore Hepatitis B, unpacking the biology, the burden, and the challenges scientists face in tackling it. If you want to hear more episodes, make sure to subscribe to the podcast. For more on how today’s discoveries are shaping tomorrow’s health, you can visit Behind the Science at GSK.com

• Transcript

If 400m+ people live with COPD, why aren’t we talking about it?

Experts Kaivan Khavandi and Dave Singh discuss diseases that affect a fundamental aspect of life – breathing. Developed and funded by GSK. Show note: In the second Behind the Science episode, Dr. Kat Arney speaks with Professor Dave Singh, a specialist in respiratory pharmacology at the University of Manchester, and Dr. Kaivan Khavandi, Senior Vice President and Global Head of Respiratory, Immunology and Inflammation Research at GSK, to take a closer look at a disease that affects a fundamental part of life – breathing. Together they explore COPD, unpacking how it affects everyday life and why severe flare-ups can have such serious consequences. If you want to hear more episodes, make sure to subscribe to the podcast. For more on how today’s discoveries are shaping tomorrow’s health, you can visit Behind the Science at GSK.com

• Transcript

Introducing: If 400m+ people live with COPD, why aren’t we talking about it?

Kaivan Khavandi & Dave Singh discuss a disease that affects a fundamental aspect of life – breathing. Episode coming soon. Developed and funded by GSK.

Are we turning the tide on superbugs?

Experts David Payne and Alison Holmes explore one of today’s biggest health challenges - antimicrobial resistance. Developed and funded by GSK. Show note: In the first Behind the Science episode, Dr. Kat Arney speaks with Professor Alison Holmes, Director of the Fleming Initiative, and David Payne, Head of Infectious Disease Research at GSK, to unpack the science, urgency and innovation behind antimicrobial resistance. If you want to listen to more episodes, make sure to subscribe to the podcast. For more on how today’s discoveries are shaping tomorrow’s health, you can visit Behind the Science at GSK.com

• Transcript

Introducing: Are we turning the tide on superbugs?

David Payne & Alison Holmes explore one of the biggest health challenges: antimicrobial resistance. Episode coming soon. Developed and funded by GSK

• Transcript